Clarification of XVIVO Perfusion’s rights to Professor Stig Steen’s media for the preservation and evaluation of organs

Due to the insufficient information that Vivoline Medical has distributed in a Memorandum (including supplementary information that was recently published) ahead of its planned new share issue and listing on AktieTorget, XVIVO Perfusion feels obliged to provide information on the exclusive global unlimited rights that XVIVO Perfusion has to certain media developed by Professor Stig Steen and Vivoline Medical for the evaluation and preservation of organs in connection with transplantation.

Pursuant to the current agreement with Professor Stig Steen and Igelösa Life Science AB, XVIVO Perfusion has global unlimited irrevocable exclusive rights to media and related patents for the preservation and evaluation of organs, media which are based on LPD (low potassium dextran) such as Perfadex®, with added calcium, created by Professor Stig Steen and Vivoline Medical.

Several of Vivoline Medical’s patent rights mentioned in its Memorandum are for media created by Professor Stig Steen for the preservation and evaluation of organs, media which are based on LPD with added calcium. These patents are thus covered by XVIVO Perfusion’s exclusive rights.

XVIVO Perfusion’s product STEEN Solution
is protected by a patent which is valid until the year 2021 and which covers evaluation and preservation solutions containing LPD in combination with the high concentrations of albumin that are considered necessary to create an effective protective environment for the organs being evaluated and stored.

Magnus Nilsson, CEO of XVIVO Perfusion: “XVIVO Perfusion intends to continue developing and commercializing Professor Stig Steen’s media in the best way possible so as to create value for patients, customers and shareholders.”

April 12, 2013
XVIVO Perfusion AB (publ)

For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59,

Xvivo Perfusion is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on April 12, 2013 at 11:45 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.


XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The Xvivo share is listed on NASDAQ OMX First North and has the ticker symbol XVIVO. More information can be found on the website The Certified Adviser is Redeye,

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: Website:



Documents & Links